Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Nektar Therapeutics    NKTR

NEKTAR THERAPEUTICS

(NKTR)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

S&P 500 Movers: NKTR, COTY

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 10:36am EST

In early trading on Tuesday, shares of Coty (COTY) topped the list of the day's best performing components of the S&P 500 index, trading up 13.8%. Year to date, Coty registers a 67.6% gain.

And the worst performing S&P 500 component thus far on the day is Nektar Therapeutics (NKTR), trading down 8.1%. Nektar Therapeutics is showing a gain of 29.5% looking at the year to date performance.

Two other components making moves today are Molson Coors Brewing (TAP), trading down 7.4%, and Brighthouse Financial (BHF), trading up 10.5% on the day.

© BNK Invest, source Videos

Stocks mentioned in the article
ChangeLast1st jan.
BRIGHTHOUSE FINANCIAL 2.47% 41.95 Delayed Quote.37.63%
MOLSON COORS BREWING 1.79% 60.91 Delayed Quote.8.46%
NEKTAR THERAPEUTICS -2.18% 41.69 Delayed Quote.26.83%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NEKTAR THERAPEUTICS
02/15NEKTAR THERAPEUTICS : Other Events (form 8-K)
AQ
02/15NEKTAR THERAPEUTICS : Clinical Data Presented from PIVOT-02 Study of Bempegaldes..
PU
02/06NEKTAR THERAPEUTICS : Amendments to Articles of Inc. or Bylaws; Change in Fiscal..
AQ
02/05U.S. jury orders Takeda to pay Bayer $155 million over haemophilia drug
RE
01/17STRAP YOURSELF IN : Netflix is about to report
RE
01/11SEATTLE GENETICS : UW team builds protein that avoids IL-2 toxicities, forms Neo..
AQ
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08NEKTAR THERAPEUTICS : Results of Operations and Financial Condition, Other Event..
AQ
01/04NEKTAR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
AQ
01/04NEKTAR THERAPEUTICS : ImaginAb Announces Immuno-Oncology License and Clinical Tr..
AQ
More news
Financials ($)
Sales 2018 1 198 M
EBIT 2018 693 M
Net income 2018 684 M
Finance 2018 979 M
Yield 2018 -
P/E ratio 2018 10,75
P/E ratio 2019
EV / Sales 2018 5,21x
EV / Sales 2019 30,2x
Capitalization 7 216 M
Chart NEKTAR THERAPEUTICS
Duration : Period :
Nektar Therapeutics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEKTAR THERAPEUTICS
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 78,9 $
Spread / Average Target 89%
EPS Revisions
Managers
NameTitle
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Research & Development Officer
Sector and Competitors
1st jan.Capitalization (M$)
NEKTAR THERAPEUTICS26.83%7 216
IQVIA HOLDINGS INC22.11%28 377
CELLTRION, INC.--.--%23 803
LONZA GROUP14.80%21 653
INCYTE CORPORATION32.33%17 908
SEATTLE GENETICS, INC.26.16%11 477